---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004455"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:06:36.774067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports 40% blinded CRc in MIRACLE trial; 35 subjects treated, unblinding on track for Q1 2026

## Summary
- Preliminary blinded composite CR rate of 40% (30% CR, 10% CRh) in first 30 subjects; 67% above historical cytarabine CR.
- 35 subjects treated to date with 11 in screening; targeting first unblinding at 45 subjects, on track for Q1 2026 treatment milestone.
- Roughly 35% of treated subjects are venetoclax regimen failures, a challenging population with high unmet need.
- Continued absence of cardiotoxicity cited; Annamycin holds FDA Fast Track and Orphan Drug Designation for R/R AML.

## SEC filing metadata
- accession: 0001437749-26-004455
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004455/0001437749-26-004455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004455/mbrx20260216c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004455
- JSON: https://secwatch.observer/filing/0001437749-26-004455.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.